Skip to Content

The Trispecific Antibody SAR’257 Discontinued After Phase 1 Findings

At ASH 2024, Fredrik Schjesvold presented the results of a phase 1 study on SAR’257, a trispecific antibody drug for treating relapsed refractory myeloma and non-Hodgkin’s lymphoma. Despite its innovative approach of targeting two T-cell receptors (CD3 and CD28), the drug showed high toxicity and low efficacy, leading to its development being discontinued. The study provided valuable insights into T-cell stimulation limits in immunotherapy.

Fredrik Schjesvold

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top